Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
26 - Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
from Section 3 - Alzheimer’s Disease Clinical Trials
Published online by Cambridge University Press: 03 March 2022
By
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
Summary
Expanded access and compassionate use refer to the use of an investigational new drug outside of a clinical trial to treat a patient with a serious or life-threatening disease who are not eligible or it is not feasible to participate in randomized, clinical trials. The Food and Drug Administration oversees the expanded-access program and provides guidance for the stakeholders. The expanded-access process provides a potential mechanism to facilitate Alzheimer’s disease (AD) drug development process and increase access to investigational new drugs for patients with AD.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 301 - 308Publisher: Cambridge University PressPrint publication year: 2022
References
Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020; 16: 391–460.Google Scholar
Cummings, J, Lee, G, Ritter, A, Sabbagh, M, Zhong, K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019; 5: 272–93.Google Scholar
Food and Drug Administration. Project Facilitate: assisting healthcare providers with expanded access requests for investigational oncology products. Available at: www.fda.gov/about-fda/oncology-center-excellence/project-facilitate (accessed October 31, 2020).Google Scholar
Jarlow, JP, Moscicki, R. Impact of expanded access on FDA regulatory action and product labeling. Ther Innov Regul Sci 2017; 51: 1–2.Google Scholar
Food and Drug Administration. Expanded access to investigational drugs for treatment use: final rule. Fed Regist 2009; 74: 40900–45.Google Scholar
Food and Drug Administration. FDA backgrounder on FDAMA. Available at: www.fda.gov/regulatory-information/food-and-drug-administration-modernization-act-fdama-1997/fda-backgrounder-fdama (accessed October 31, 2020).Google Scholar
Food and Drug Administration. Expanded Access Program Report. 2018. Available at: www.fda.gov/media/119971/download (accessed October 31, 2020).Google Scholar
Center for Drug Evaluation and Research. CDER NextGen Portal. Available at: https://edm.fda.gov/ (accessed October 31, 2020).Google Scholar
Food and Drug Administration. 21st Century Cures Act. Available at: www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act (accessed October 31, 2020).Google Scholar
Center for Drug Evaluation and Research. Guidance for Industry: Expanded Access to Investigational Drugs for Treatment Use-Questions and Answers, Maryland: FDA; 2017.Google Scholar
Jarow, JP, Lurie, P, Crowley Ikenberry, S, Lemery, S. Overview of FDA’s expanded access program for investigational drugs. Ther Innov Regul Sci 2017; 51: 177–9.Google Scholar
Borysowski, J, Ehni, H-J, Górski, A. Ethics review in compassionate use. BMC Med 2017; 15: 136–42.Google Scholar
Food and Drug Administration. IRB review of individual patient expanded access requests for investigational drugs and biological products during the COVID-19 public health emergency. June 2020. Available at: www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-board-irb-review-individual-patient-expanded-access-requests-investigational (accessed October 31, 2020).Google Scholar
Chapman, CR, Eckman, J, Bateman-House, AS. Oversight of right-to-try and expanded access requests for off-trial access to investigational drugs. Ethics Hum Res 2020; 42: 2–13.Google Scholar
Porcino, A, Shamseer, L, Chan, A-W, et al. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ 2020; 368: m122.CrossRefGoogle ScholarPubMed
Jarow, JP, Lemery, S, Bugin, K, Khozin, S, Moscicki, R. Expanded access of investigational drugs: the experience of the center of drug evaluation and research over a 10-year period. Ther Innov Regul Sci 2016; 50: 705–9.Google Scholar
McKee, AE, Markon, AO, Chan-Tack, KM, Lurie, P. How often are drugs made available under the Food and Drug Administration’s expanded access process approved? J Clin Pharmacol 2017; 57: S136–42.Google Scholar